Regulation of Health Care Professionals: Regulation of Social Care Professionals in England: The Government’s response to Law Commission report 345, Scottish Law Commission report 237 and Northern Ireland Law Commission report 18 (2014) Cm 8839 SG/2014/26

The response sets out the government’s approach to public protection and how this can be supported by professional regulation, it covers: • the structure of reform • the make-up of a regulatory body • registers and registration • education, standards

The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation – Health Technology Assessment

Study that aims to assess the effectiveness and cost-effectiveness of diversion and aftercare for class A drug-using offenders, compared with no diversion.  Finds that high-quality evidence for the effectiveness and cost-effectiveness of diversion schemes is sparse and does not relate

Secondary analysis and literature review of community rehabilitation and intermediate care: an information resource – Health Services and Delivery Research

This study provides additional evidence that interdisciplinary teamworking in Intermediate Care may be associated with better outcomes for patients, but care should be taken with overinterpretation. The measures that were used within the studies were found to be reliable, valid

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation – Health Technology Assessment

Aims to determine the comparative clinical effectiveness and cost-effectiveness of topotecan (Hycamtin®, GlaxoSmithKline), pegylated liposomal doxorubicin hydrochloride (PLDH; Caelyx®, Schering-Plough), paclitaxel (Taxol®, Bristol-Myers Squibb), trabectedin (Yondelis®, PharmaMar) and gemcitabine (Gemzar®, Eli Lilly and Company) for the treatment of advanced, recurrent